Levodopa Response in Patients With Early Parkinson Disease Further Observations of the LEAP Study

被引：14

作者：

Frequin, Henrieke L. ^{[1
]}

Schouten, Jason ^{[1
]}

Verschuur, Constant V. M. ^{[1
]}

Suwijn, Sven R. ^{[1
]}

Boel, Judith A. ^{[2
]}

Post, Bart ^{[3
]}

Bloem, Bastiaan R. ^{[3
]}

van Hilten, Johannes J. ^{[4
]}

van Laar, Teus ^{[5
]}

Tissingh, Gerrit ^{[6
]}

Munts, Alexander G. ^{[7
]}

Dijk, Joke M. ^{[1
]}

Deuschl, Gunther ^{[8
]}

Lang, Anthony ^{[9
]}

Dijkgraaf, Marcel G. W. ^{[10
]}

de Haan, Rob J. ^{[11
]}

de Bie, Rob M. A. ^{[1
]}

机构：

[1] Amsterdam Univ Med Ctr, Dept Neurol, Amsterdam, Netherlands

[2] Amsterdam Univ Med Ctr, Dept Med Psychol, Amsterdam, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands

[4] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands

[5] Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands

[6] Zuyderland Med Ctr, Dept Neurol, Heerlen, Netherlands

[7] Excellent Klinieken, Dept Neurol, Dordrecht, Netherlands

[8] Univ Med Ctr Schleswig Holstein, Dept Neurol, Kiel, Germany

[9] Univ Toronto, Dept Neurol, Toronto Western Hosp, Toronto, ON, Canada

[10] Amsterdam Univ Med Ctr, Dept Epidemiol & Data Sci, Amsterdam, Netherlands

[11] Amsterdam Univ Med Ctr, Clin Res Unit, Amsterdam, Netherlands

来源：

NEUROLOGY | 2023年 / 100卷 / 04期

关键词：

LONG-DURATION RESPONSE; DELAYED-START; THERAPY; TRIAL;

D O I：

10.1212/WNL.0000000000201448

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background and Objectives The Levodopa in EArly Parkinson's Disease (LEAP) study enabled us to conduct post hoc analyses concerning the effects of levodopa in patients with early Parkinson disease. Methods The LEAP study was a double-blind, placebo-controlled, randomized, delayed-start trial in which patients with early Parkinson disease were randomized to receive levodopa/carbidopa 300/75 mg daily for 80 weeks (early-start group) or to placebo for 40 weeks followed by levodopa/carbidopa 300/75 mg daily for 40 weeks (delayed-start group). We analyzed the effect of levodopa with the Unified Parkinson's Disease Rating Scale on bradykinesia, rigidity, and tremor. At week 80, participants answered 3 questions regarding motor response fluctuations. Results A total of 222 patients were randomized to the early-start group (mean +/- SD age at baseline 64.8 +/- 8.7 years; 71% male) and 223 to the delayed-start group (mean +/- SD age at baseline 65.5 +/- 8.8 years; 69% male). The difference between the early- and delayed-start groups in mean change from baseline to week 4, expressed as Hedges g effect size, was -0.33 for bradykinesia, -0.29 for rigidity, and -0.25 for tremor (for all symptoms indicating a small effect in favor of the early-start group); from baseline to week 22, respectively, -0.49, -0.36, and -0.44 (small to medium effect); and from baseline to week 40, respectively, -0.32, -0.19, and -0.27 (small effect). At 80 weeks, fewer patients in the early-start group (46 of 205 patients, 23%) experienced motor response fluctuations than patients in the delayed-start group (81 of 211, 38%; p < 0.01). Discussion In patients with early Parkinson disease, levodopa improves bradykinesia, rigidity, and tremor to the same order of magnitude. For all 3 symptoms, effects were larger at 22 weeks compared with 4 weeks. At 80 weeks, there were fewer patients with motor response fluctuations in the group that had started levodopa earlier.

引用

页码：E367 / E376

页数：10

共 21 条

[1] The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications
Anderson, Elise
Nutt, John
[J]. PARKINSONISM & RELATED DISORDERS, 2011, 17 (08) : 587 - 592
[2] Biglan KM, 2009, ARCH NEUROL-CHICAGO, V66, P563, DOI 10.1001/archneur.66.1.nct90001
[3] Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa
Cilia, Roberto
Cereda, Emanuele
Akpalu, Albert
Sarfo, Fred Stephen
Cham, Momodou
Laryea, Ruth
Obese, Vida
Oppon, Kenneth
Del Sorbo, Francesca
Bonvegna, Salvatore
Zecchinelli, Anna Lena
Pezzoli, Gianni
[J]. BRAIN, 2020, 143 (08) : 2490 - 2501
[4] The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Cilia, Roberto
Akpalu, Albert
Sarfo, Fred Stephen
Cham, Momodou
Amboni, Marianna
Cereda, Emanuele
Fabbri, Margherita
Adjei, Patrick
Akassi, John
Bonetti, Alba
Pezzoli, Gianni
[J]. BRAIN, 2014, 137 : 2731 - 2742
[5] The Delayed-Start Study Design
D'Agostino, Ralph B., Sr.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) : 1304 - 1306
[6] Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
de Bie, Rob M. A.
Clarke, Carl E.
Espay, Alberto J.
Fox, Susan H.
Lang, Anthony E.
[J]. LANCET NEUROLOGY, 2020, 19 (05) : 452 - 461
[7] Fahn S, 2004, NEW ENGL J MED, V351, P2498
[8] Fahn S., 1987, Recent developments in Parkinsons disease, V2
[9] Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
Hauser, RA
Holford, NHG
[J]. MOVEMENT DISORDERS, 2002, 17 (05) : 961 - 968
[10] Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Hauser, Robert A.
Rascol, Olivier
Korczyn, Amos D.
Stoessl, A. Jon
Watts, Ray L.
Poewe, Werner
De Deyn, Peter P.
Lang, Anthony E.
[J]. MOVEMENT DISORDERS, 2007, 22 (16) : 2409 - 2417

← 1 2 3 →